Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,255 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Dabur delivered a solid Q3 with consolidated revenue of INR 3,255 crore (+7% YoY) and 6% volume growth in India FMCG. Gross margin expanded 310 bps on material deflation, while operating profit grew 9.5% with 50 bps margin expansion. International business grew 11.7% in CC, led by MENA and Egypt. Rural growth outpaced urban by 200 bps, driven by distribution expansion to 1.17 lakh villages and 18,700 Yoddhas. The healthcare portfolio was muted due to delayed winters, but HPC and oral care gained market share. Management remains cautiously optimistic, guiding for continued margin expansion and rural recovery. Key risk: sustained food inflation could pressure rural demand and delay recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management committed to exiting the fiscal year with a run rate of INR 500 crore from the foods portfolio, including Badshah.
- Direct distribution reach to increase from 1.42 million to 1.5 million outlets by end of FY24.
- Management expects Q4 EBITDA margin expansion to be higher than the 50 bps seen in the first nine months, despite seasonal mix effects.
- Legal costs related to the U.S. case are expected to be lower in FY25 due to a change to more cost-effective lawyers.
Risks flagged
- Muted and delayed winters led to flat growth in Chyawanprash, though inventory is expected to clear in Q4.
- Food inflation in fruits, vegetables, spices, and cereals remains high, potentially delaying rural recovery despite Dabur's outperformance.
- The U.S. patent litigation continues to incur legal costs (~INR 20 crore per quarter), though scope has been narrowed and insurance may cover final damages.
- Historical Q4 margins are lower due to product mix; management expects expansion but sequential decline is possible.
Key quotes
- Our rural growth is in the range of around 6-6.5% as compared to urban, which is around 3.8%, which consolidates around 5% growth.
- We remain committed to exiting the year with a run rate of INR 500 crore from our foods portfolio, including Badshah.
- The expansion in margins will continue, albeit at a slightly faster pace in Q4.
Research modules